Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment.
Primary CNS lymphomas (PCNSL) represent malignant non-Hodgkin's B cell lymphomas, which are confined to the central nervous system. They show a dramatic increase in frequency in the immunocompromised as well as in the immunocompetent population. Recent studies have identified germinal center B cells as the cellular origin of PCNSL; however, the details of their molecular pathogenesis still remain to be elucidated. Treatment recommendations are not clearly established. Radiotherapy (RT) is efficient in terms of tumor response, but not curative. Median survival after RT alone is about 1 year. According to the results of uncontrolled studies the combination of RT and chemotherapy based on high-dose methotrexate (HD-MTX) is most efficient in terms of survival rates. However, long-term neurotoxicity overshadows treatment efficacy, especially in patients over 60 years of age. The authors favor the systematic evaluation of chemotherapy alone with protocols including HD MTX, because unicenter results are promising in terms of both survival as well as quality of life in long term survivors.
Schlegel
U
U
Department of Neurology, University Medical Center, Sigmund-Freud-Str. 25, D-53105, Bonn, Germany. uwe.schlegal@uni-bonn.de
Schmidt-Wolf
I G
IG
Deckert
M
M
D016543:Central Nervous System Neoplasms / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D003937:Diagnosis, Differential; D004358:Drug Therapy / Q000379:methods / Q000706:statistics & numerical data; D015658:HIV Infections / Q000150:complications; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods / Q000706:statistics & numerical data; D015996:Survival Rate / Q000639:trends